Net Income

HealthEquity adds Sanford Health CEO Bill Gassen to its board, a strategic move to infuse provider-side expertise into the HSA giant's future.

With a fresh $6M infusion bringing its Series A to $36M, FIZE Medical is accelerating its global push for AI-powered, proactive fluid management in ICUs.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

South Korean AI chip leader Rebellions raises $400M, launching full-stack AI systems to redefine efficient inference and spearhead a global expansion.

Aurinia Pharmaceuticals' deal for Kezar Life Sciences hinges on zetomipzomib, a promising but risky drug poised to tackle a rare autoimmune liver disease.

As Precigen leaders prepare for a key investor chat, all eyes are on the explosive launch of PAPZIMEOS and the company's ambitious path to profitability.

Food-tech firm Beyond Oil is rolling out its oil-purifying tech in a top U.S. supermarket, promising healthier fried food and significant cost savings.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

After a transformative year with key FDA/EU approvals, Pulsenmore's financials get a one-time boost. Can it now conquer the remote prenatal care market?

Husqvarna's new residential mowers boast major comfort and durability upgrades, heating up the spring sales battle against John Deere, Toro, and Cub Cadet.

Clearwater Paper launches Velora™, a new lightweight paperboard balancing cost, sustainability, and domestic supply to capture the everyday packaging market.

Australian medtech firm 4DMedical lands CE Mark for its revolutionary CT:VQ lung imaging, fueling a major European expansion with a fresh AU$83M investment.

A $15M grant fuels a revolutionary therapy for a fatal childhood disease, turning patients' own cells into 'living biofactories' to fight MPS I.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.

As millions grapple with Cannabis Use Disorder, a small biotech's lead drug enters Phase 3 trials, promising the first-ever FDA-approved treatment.

PMGC Holdings touts major acquisitions and a promising biotech pipeline, but a look at its financials reveals a high-stakes bet on future growth.

Magnachip's new power semiconductors promise major efficiency and density gains for servers, tackling the soaring energy needs of the growing AI boom.

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.